- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.11.24 | How the 'five Ps' can close health equity gaps | ||
| 27.11.24 | Novartis' Kisqali granted EC approval to treat early breast cancer patients | ||
| 27.11.24 | GSK's linerixibat shows promise in phase 3 primary biliary cholangitis trial | ||
| 27.11.24 | FDA approves Shorla Oncology's Imkeldi to treat leukaemia and other cancers | ||
| 27.11.24 | All hands on deck | ||
| 26.11.24 | Roche expands cell therapy capabilities with $1.5bn Poseida acquisition | ||
| 26.11.24 | AstraZeneca announces $3.5bn US investment to boost research and manufacturing | ||
| 26.11.24 | Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis | ||
| 26.11.24 | Langland appoints Gemma Cathcart as managing partner | ||
| 26.11.24 | Why the patient voice is the secret to re-energising the healthcare sector | ||
| 25.11.24 | Novartis and Ratio enter radiotherapeutics partnership worth $745m | ||
| 25.11.24 | J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis | ||
| 25.11.24 | FDA approves BridgeBio Pharma's Attruby to treat rare heart disease ATTR-CM | ||
| 25.11.24 | Delivering real value through live meetings: the power of interactive formats | ||
| 25.11.24 | More is different | ||
| 22.11.24 | PMEA 2024: a celebration of excellence in pharmaceutical marketing | ||
| 22.11.24 | Pfizer's Hympavzi receives EC approval to treat haemophilia A and B patients | ||
| 22.11.24 | Cutting through the noise: using data and creativity to revolutionise healthcare communications | ||
| 21.11.24 | EAACI launches first World Anaphylaxis Awareness Day | ||
| 21.11.24 | Pfizer appoints Chris Boshoff as chief scientific officer and president of R&D | ||
| 21.11.24 | Measuring outcomes in medical affairs - the key components to be considered | ||
| 20.11.24 | UCB's Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults | ||
| 20.11.24 | Is the new Health and Social Care Select Committee a battleground or consensus opportunity? | ||
| 20.11.24 | Bringing more effective storytelling to medical publications | ||
| 19.11.24 | Biogen/Eisai's Alzheimer's drug lecanemab receives CHMP recommendation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
